Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…

Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Gynaecomastia

Endocrinology and metabolism · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Escalate

A hard eccentric breast mass, nipple retraction or bloody discharge, skin tethering, pathological nodes or a testicular mass needs urgent suspected-cancer assessment under current NICE referral guidance. Acute testicular pain follows the torsion pathway. Do not reassure from the word gynaecomastia before examining breast, nodes and testes.

Synopsis

Confirm true glandular breast enlargement, detect breast or testicular malignancy and endocrine disease, remove reversible causes, and treat persistent pain or distress through an appropriate breast pathway.

  • True gynaecomastia is benign proliferation of glandular breast tissue, usually felt as a rubbery or firm concentric subareolar disc; adipose enlargement without gland is pseudogynaecomastia.
  • Physiological gynaecomastia occurs in newborns, puberty and later life, but the age does not remove the need to investigate a suspicious eccentric mass or systemic clue.
  • The mechanism is increased oestrogen effect relative to androgen action from gonadal failure, liver or thyroid disease, tumours, medicines or exogenous hormones.
  • Take a complete prescribed, over-the-counter, private and substance history, including spironolactone, anti-androgens, finasteride, antipsychotics, anabolic steroids, cannabis and supplements.
  • A unilateral tender subareolar disc can still be benign; cancer is more concerning when hard, irregular, eccentric, fixed or associated with nipple, skin or nodal change.
  • Examine testes because an hCG- or oestrogen-producing testicular tumour can present through breast enlargement before the patient reports a testicular symptom.
  • Laboratory testing is targeted by age, duration and findings; testosterone with LH and FSH, oestradiol, hCG, prolactin, thyroid, liver and renal tests are not an automatic panel for every pubertal case.
  • New tender glandular tissue may respond to removal of the cause or specialist medical treatment, while long-standing fibrotic tissue is less likely to regress pharmacologically.
  • Persistent pain, marked asymmetry or psychological distress deserves active care and a surgical discussion where appropriate, although NHS commissioning criteria vary locally.

Key red flags

Male breast cancer pattern

A hard irregular eccentric mass, skin dimpling, nipple inversion, unilateral bloody discharge or axillary nodes is suspicious and needs urgent breast referral.

Testicular tumour clue

A firm intratesticular mass, asymmetry, heaviness or recent rapid gynaecomastia can reflect hCG or oestrogen production and requires urgent testicular assessment.

Liver or thyroid phenotype

Jaundice, spider naevi, ascites, muscle loss or testicular atrophy suggests liver disease; tremor, weight loss, heat intolerance and tachycardia suggests thyrotoxicosis.

Investigation priorities

01
Breast, node and testicular examinationFirst step

Distinguish gland, fat and suspicious masses and identify a gonadal source.

Management branches

TriageMale breast enlargement

A person presents with unilateral or bilateral breast swelling, tenderness or a lump.

  1. Clarify duration, pain, nipple change, weight change, puberty, sexual and fertility symptoms, organ disease, family cancer risk, radiotherapy, medicines, anabolic agents, alcohol and supplements.
  2. Examine both breasts and nodes and distinguish subareolar gland from diffuse fat or an eccentric lesion; examine testes and secondary sexual characteristics with consent.
  3. Send any suspicious breast feature to the urgent NICE breast pathway and any testicular mass to urgent urology rather than ordering a routine endocrine panel first.
  4. For a typical benign presentation, decide whether age and history support observation or targeted testosterone, gonadotrophin, hCG, oestradiol, prolactin, thyroid, liver and renal testing.

Key medicines

Tamoxifen specialist treatmentUse only the short specialist-selected off-label course for recent painful proliferative gynaecomastia.Assess venous thrombosis, visual symptoms, liver disease and interacting medicines and explain off-label use. It is not a substitute for evaluating cancer, testicular mass or endocrine cause.
Testosterone replacementUse a licensed formulation and specialist-titrated regimen only after symptomatic hypogonadism is repeatedly confirmed.It suppresses spermatogenesis, needs haematocrit and prostate monitoring and can aromatise to oestradiol; it may not shrink chronic glandular tissue and is not empirical breast-lump treatment.
Open full textbook →Answer 2 questions
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • NICE NG12 suspected-cancer recommendationsUpdated 2026 breast and testicular referral features.
  • NHS gynaecomastia informationCauses, symptoms, medical review and treatment overview.
  • Association of Breast Surgery information hubUK specialist breast guidance and symptomatic-imaging resources.
  • NICE CKS breast-cancer recognitionClinical cancer features and urgent referral.
  • BNF testosterone monographReplacement indications, contraindications and monitoring.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom